José Palacios

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3167714/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 2017, 3, e173290.	7.1	260
2	Molecular genetic heterogeneity in undifferentiated endometrial carcinomas. Modern Pathology, 2016, 29, 1390-1398.	5.5	80
3	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology: Clinical Research, 2018, 4, 250-261.	3.0	70
4	MicroRNA-Dependent Regulation of Transcription in Non-Small Cell Lung Cancer. PLoS ONE, 2014, 9, e90524.	2.5	65
5	Exome sequencing identifies ATP4A gene as responsible of an atypical familial type I gastric neuroendocrine tumour. Human Molecular Genetics, 2015, 24, 2914-2922.	2.9	60
6	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	7.0	43
7	Activated leukocyte cell adhesion molecule (<scp>ALCAM</scp>) is a marker of recurrence and promotes cell migration, invasion, and metastasis in earlyâ€stage endometrioid endometrial cancer. Journal of Pathology, 2017, 241, 475-487.	4.5	42
8	Autoregulatory loop of nuclear corepressor 1 expression controls invasion, tumor growth, and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E328-37.	7.1	41
9	Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. Histopathology, 2016, 68, 45-56.	2.9	37
10	Aurora kinases as prognostic biomarkers in ovarian carcinoma. Human Pathology, 2009, 40, 631-638.	2.0	35
11	High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. Oncologist, 2016, 21, 150-155.	3.7	35
12	Treating <i>KRAS</i> -mutant NSCLC: latest evidence and clinical consequences. Therapeutic Advances in Medical Oncology, 2017, 9, 589-597.	3.2	33
13	High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features. Cancers, 2019, 11, 74.	3.7	33
14	18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial. Clinical Cancer Research, 2017, 23, 1432-1441.	7.0	32
15	The NER-related gene <i>GTF2H5</i> predicts survival in high-grade serous ovarian cancer patients. Journal of Gynecologic Oncology, 2016, 27, e7.	2.2	30
16	Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma. Cancers, 2020, 12, 1832.	3.7	30
17	Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study. Human Pathology, 2018, 72, 100-106.	2.0	28
18	The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407). Oncologist, 2020, 25, 745-e1265.	3.7	25

JOSé PALACIOS

#	Article	IF	CITATIONS
19	Molecularly determined total tumour load in lymph nodes of stage I–II colon cancer patients correlates with high-risk factors. A multicentre prospective study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 385-394.	2.8	24
20	A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry. Human Pathology, 2014, 45, 2394-2403.	2.0	18
21	RNA SARS-CoV-2 Persistence in the Lung of Severe COVID-19 Patients: A Case Series of Autopsies. Frontiers in Microbiology, 2022, 13, 824967.	3.5	18
22	Deletion at 6q24.2–26 predicts longer survival of highâ€grade serous epithelial ovarian cancer patients. Molecular Oncology, 2015, 9, 422-436.	4.6	17
23	The nuclear corepressor 1 and the thyroid hormone receptor β suppress breast tumor lymphangiogenesis. Oncotarget, 2016, 7, 78971-78984.	1.8	15
24	Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. Oncologist, 2017, 22, 1301-1308.	3.7	13
25	Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma. International Journal of Molecular Sciences, 2021, 22, 7398.	4.1	13
26	CK19 expression in breast tumours and lymph node metastasis after neoadjuvant therapy. Histopathology, 2016, 69, 239-249.	2.9	12
27	Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes. British Journal of Cancer, 2017, 117, 1048-1062.	6.4	12
28	Pulmonary vascular proliferation in patients with severe COVID-19: an autopsy study. Thorax, 2021, 76, 1044-1046.	5.6	12
29	Pleomorphic lobular carcinoma of the breast with osteoclast-like giant cells: a case report and review of the literature. Diagnostic Pathology, 2018, 13, 62.	2.0	11
30	Late Cardiac Pathology in Severe Covid-19. A Postmortem Series of 30 Patients. Frontiers in Cardiovascular Medicine, 2021, 8, 748396.	2.4	9
31	Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis. Cancers, 2021, 13, 5416.	3.7	7
32	Reproducibility of mRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancer—A Europe-Wide External Quality Assessment. Cancers, 2021, 13, 4718.	3.7	6
33	Comparison of the Idyllaâ,,¢ MSI assay with the Promegaâ,,¢ MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 1031-1039.	2.8	6
34	Low Prevalence of HER2-Positive Breast Carcinomas among Screening Detected Breast Cancers. Cancers, 2020, 12, 1578.	3.7	5
35	Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases. Cancers, 2022, 14, 1151.	3.7	5
36	Molecular Heterogeneity of High Grade Colorectal Adenocarcinoma. Cancers, 2021, 13, 233.	3.7	4

JOSé PALACIOS

#	Article	IF	CITATIONS
37	Next generation sequencing to decipher concurrent loss of PMS2 and MSH6 in colorectal cancer. Diagnostic Pathology, 2020, 15, 84.	2.0	3
38	Nabrax: Neoadjuvant therapy of breast cancer with weekly single-agent nab-paclitaxel—Final efficacy and biomarkers analysis of GEICAM 2011-02 trial Journal of Clinical Oncology, 2014, 32, 1051-1051.	1.6	3
39	Impact of the COVID-19 pandemic on pathology training: a survey among Spanish residents. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 505-509.	2.8	3
40	Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: a position statement of SEOM, SEAP and SEFH. Farmacia Hospitalaria, 2017, 41, 688-691.	0.6	3
41	Histological changes secondary to wire coil placement in breast tissue and lymph nodes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 285-291.	2.8	2
42	A phase II trial to assess the activity and safety of the hypoxia-activated prodrug evofosfamide (TH-302) in combination with sunitinib in patients with disseminated grade 1 and 2 pancreatic neuroendocrine tumors (pNET) as a first-line approach: The GETNE-1408 trial Journal of Clinical Oncology, 2016, 34, TPS479-TPS479.	1.6	2
43	Central pathology review of early-stage ovarian carcinoma: Description and correlation with follow-up—A study by the Spanish Group for Ovarian Cancer Research (GEICO) Journal of Clinical Oncology, 2014, 32, 5583-5583.	1.6	2
44	Cytological and molecular characterization of secretory breast carcinoma. Diagnostic Cytopathology, 2022, , .	1.0	2
45	Acute Dyspnea and Hemoptysis in an 84-Year-Old Man With Multiple Comorbidities. Chest, 2022, 161, e97-e101.	0.8	1
46	Necitumumab in squamous non-small-cell lung cancer: how to move forward?. Annals of Oncology, 2016, 27, 1374-1376.	1.2	0
47	MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology Journal of Clinical Oncology, 2021, 39, 558-558.	1.6	0
48	Survival surrogates in gastric cancer after first- and second-line chemotherapy treatment: A Spanish retrospective study from one institution Journal of Clinical Oncology, 2014, 32, e15019-e15019.	1.6	0
49	Prognostic factors in advanced gastric cancer after second-line treatment Journal of Clinical Oncology, 2015, 33, 201-201.	1.6	0
50	Clinicopathological Significance of Taz and VGLL1 Expression in Early Stage Ovarian Cancer. A study by Spanish Group for Ovarian Cancer Research (GEICO) Journal of Clinical Oncology, 2015, 33, e16583-e16583.	1.6	0
51	CD8+ TILs in early stage epithelial ovarian cancer: A GEICO study Journal of Clinical Oncology, 2017, 35, 5543-5543.	1.6	0
52	Immuneâ€related gene expression signatures: a step forward in the stratification of patients with ovarian clear cell carcinoma â€. Journal of Pathology, 2021, , .	4.5	0